NO323633B1 - Farmasoytisk aktive isoindolderivater - Google Patents

Farmasoytisk aktive isoindolderivater

Info

Publication number
NO323633B1
NO323633B1 NO20022223A NO20022223A NO323633B1 NO 323633 B1 NO323633 B1 NO 323633B1 NO 20022223 A NO20022223 A NO 20022223A NO 20022223 A NO20022223 A NO 20022223A NO 323633 B1 NO323633 B1 NO 323633B1
Authority
NO
Norway
Prior art keywords
pharmaceutically active
isoindole derivatives
isoindole
derivatives
oxoisoindoline
Prior art date
Application number
NO20022223A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022223L (no
NO20022223D0 (no
Inventor
George W Muller
Hon-Wah Man
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of NO20022223D0 publication Critical patent/NO20022223D0/no
Publication of NO20022223L publication Critical patent/NO20022223L/no
Publication of NO323633B1 publication Critical patent/NO323633B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20022223A 1999-11-12 2002-05-08 Farmasoytisk aktive isoindolderivater NO323633B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16516899P 1999-11-12 1999-11-12
US59034400A 2000-06-08 2000-06-08
US09/708,199 US6667316B1 (en) 1999-11-12 2000-11-08 Pharmaceutically active isoindoline derivatives
PCT/US2000/030770 WO2001034606A1 (en) 1999-11-12 2000-11-09 Pharmaceutically active isoindoline derivatives

Publications (3)

Publication Number Publication Date
NO20022223D0 NO20022223D0 (no) 2002-05-08
NO20022223L NO20022223L (no) 2002-07-08
NO323633B1 true NO323633B1 (no) 2007-06-18

Family

ID=27389110

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20022223A NO323633B1 (no) 1999-11-12 2002-05-08 Farmasoytisk aktive isoindolderivater
NO20071490A NO336210B1 (no) 1999-11-12 2007-03-21 Farmasøytisk aktive isoindolderivater, anvendelse derav samt farmasøytisk preparat omfattende et slikt derivat.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20071490A NO336210B1 (no) 1999-11-12 2007-03-21 Farmasøytisk aktive isoindolderivater, anvendelse derav samt farmasøytisk preparat omfattende et slikt derivat.

Country Status (19)

Country Link
US (1) US6667316B1 (https=)
EP (4) EP1228071B8 (https=)
JP (1) JP5116201B2 (https=)
CN (1) CN1325497C (https=)
AT (4) ATE506058T1 (https=)
AU (2) AU782409B2 (https=)
CA (1) CA2392081C (https=)
CY (2) CY1107610T1 (https=)
DE (1) DE60034139T2 (https=)
DK (2) DK1228071T3 (https=)
ES (4) ES2282147T3 (https=)
FI (1) FI119931B (https=)
HK (1) HK1049158A1 (https=)
MX (1) MXPA02004793A (https=)
NO (2) NO323633B1 (https=)
NZ (1) NZ519459A (https=)
PT (2) PT1228071E (https=)
SI (1) SI1228071T1 (https=)
WO (1) WO2001034606A1 (https=)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
CN1518447A (zh) 2001-04-23 2004-08-04 �������Ǵ�ѧר������� 作为抗血管生成剂的新的苯邻二甲酰亚胺模拟物的合成和评估
NZ531294A (en) * 2001-08-06 2005-11-25 Childrens Medical Center Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2258363A1 (en) * 2002-05-17 2010-12-08 Celgene Corporation Compositions for treatment of cancers
CN1713905A (zh) 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
AU2003285107B2 (en) * 2002-10-31 2008-01-10 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
TW200501945A (en) * 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1581205A1 (en) * 2002-11-18 2005-10-05 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
BR0317885A (pt) * 2002-12-30 2005-12-06 Celgene Corp Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa
WO2004080393A2 (en) * 2003-03-06 2004-09-23 Celgene Corporation Selective cytokine inhibitory drugs for treating disorders of the central nervous system
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN100427465C (zh) * 2003-03-12 2008-10-22 细胞基因公司 N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
JP4713465B2 (ja) 2003-03-12 2011-06-29 セルジーン コーポレイション ７−アミド−イソインドリル化合物およびその薬学的使用
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
BRPI0418801A (pt) * 2004-05-05 2007-10-16 Celgene Corp métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit
JP2007536221A (ja) * 2004-05-05 2007-12-13 セルジーン・コーポレーション 骨髄増殖性疾患を治療及び管理するための選択的サイトカイン阻害薬の使用方法及びそれを含む組成物
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
CA2578789A1 (en) * 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
KR20070092276A (ko) * 2004-12-13 2007-09-12 셀진 코포레이션 Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
JP2011515469A (ja) * 2008-03-24 2011-05-19 セルジーン コーポレイション シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
EP2344479B1 (en) * 2008-09-23 2015-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
US8563580B2 (en) * 2008-09-23 2013-10-22 Georgetown University Flavivirus inhibitors and methods for their use
EP2395995A1 (en) 2009-02-10 2011-12-21 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
CN108059635B (zh) 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
ES2469849T3 (es) 2009-06-18 2014-06-20 Concert Pharmaceuticals Inc. Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
ES2451350T3 (es) 2009-10-09 2014-03-26 Celgene Corporation Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
BR112012015129A2 (pt) * 2009-12-22 2019-09-24 Celgene Corp "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
EP2583098B1 (en) 2010-06-15 2018-08-08 Celgene Corporation Biomarkers for the treatment of psoriasis
EP2663549B1 (en) * 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
JP2014505054A (ja) * 2011-01-10 2014-02-27 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの経口剤形
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
ES2711100T3 (es) 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
WO2013025897A1 (en) 2011-08-16 2013-02-21 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
RU2627471C2 (ru) * 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
BR112017019850A2 (pt) * 2015-03-19 2018-06-05 Cipla Ltd ?processo melhorado para a preparação de apremilast?
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
HU231259B1 (hu) 2016-02-04 2022-06-28 Egyt Gyogyszervegyeszeti Gyar Eljárás pomalidomide elõállítására
AU2017317123B9 (en) * 2016-08-22 2021-11-25 Medshine Discovery Inc. PDE4 inhibitor
CN107698484B (zh) * 2017-11-13 2020-05-19 广东中科药物研究有限公司 一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (en) 2018-01-17 2019-07-25 Cadila Healthcare Limited Pharmaceutical compositions for treatment of vitiligo
AU2019254962C1 (en) 2018-04-17 2023-04-27 Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd Isoindole derivatives
WO2020020101A1 (zh) * 2018-07-22 2020-01-30 上海星叶医药科技有限公司 苯并异硒唑酮胺类化合物及其制备方法和用途
CN110003084B (zh) * 2019-03-15 2022-08-02 华南师范大学 一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) * 2020-01-09 2023-01-17 常州大学 作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
CN117203196A (zh) * 2020-12-14 2023-12-08 拜欧斯瑞克斯公司 Pde4降解剂、药物组合物和治疗应用
WO2022194096A1 (zh) * 2021-03-15 2022-09-22 深圳福沃药业有限公司 雌激素受体调节剂
CN114790164B (zh) * 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
CN116354857B (zh) * 2023-03-01 2025-01-21 中国人民解放军海军军医大学 一种β-氨基砜及其衍生物的制备方法
CN120000645A (zh) * 2023-11-14 2025-05-16 赣州和美药业股份有限公司 白塞综合征的治疗
WO2025103430A1 (zh) * 2023-11-14 2025-05-22 天津合美医药科技有限公司 干燥综合征的预防或治疗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv) 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en) 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
CA2227237C (en) 1995-07-26 2005-12-13 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
PT871439E (pt) 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
WO1998005635A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
HUP0003761A3 (en) * 1997-07-31 2001-04-28 Celgene Corp Warren Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Also Published As

Publication number Publication date
CN1420889A (zh) 2003-05-28
JP5116201B2 (ja) 2013-01-09
ATE544451T1 (de) 2012-02-15
CY1107610T1 (el) 2013-03-13
CY1112707T1 (el) 2016-02-10
ES2282147T3 (es) 2007-10-16
DE60034139D1 (de) 2007-05-10
NO20022223L (no) 2002-07-08
AU782409B2 (en) 2005-07-28
NO20022223D0 (no) 2002-05-08
EP1228071A4 (en) 2002-12-04
NO20071490L (no) 2002-07-08
ES2381174T3 (es) 2012-05-23
DE60034139T2 (de) 2007-12-06
FI20020892L (fi) 2002-06-20
CN1325497C (zh) 2007-07-11
HK1053467A1 (en) 2003-10-24
AU2005202964A1 (en) 2005-08-11
AU2005202964B2 (en) 2007-11-22
EP2255801A1 (en) 2010-12-01
EP1228071A1 (en) 2002-08-07
JP2004500346A (ja) 2004-01-08
NZ519459A (en) 2003-11-28
DK2263669T3 (da) 2012-04-23
CA2392081C (en) 2010-01-05
FI119931B (fi) 2009-05-15
EP1698334B1 (en) 2011-04-20
PT1228071E (pt) 2007-05-31
ES2380574T3 (es) 2012-05-16
EP1228071B8 (en) 2012-02-29
PT2263669E (pt) 2012-04-23
WO2001034606A1 (en) 2001-05-17
EP2255801B1 (en) 2012-02-08
MXPA02004793A (es) 2003-10-14
SI1228071T1 (sl) 2007-08-31
EP1228071B1 (en) 2007-03-28
DK1228071T3 (da) 2007-08-06
CA2392081A1 (en) 2001-05-17
ATE544452T1 (de) 2012-02-15
ES2363933T3 (es) 2011-08-19
HK1049158A1 (zh) 2003-05-02
ATE506058T1 (de) 2011-05-15
US6667316B1 (en) 2003-12-23
FI20020892A0 (fi) 2002-05-10
EP2263669B1 (en) 2012-02-08
AU1478001A (en) 2001-06-06
ATE357913T1 (de) 2007-04-15
EP1698334A1 (en) 2006-09-06
NO336210B1 (no) 2015-06-15
EP2263669A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
NO20022223L (no) Farmasöytisk aktive isoindolderivater
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
NO20002217D0 (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
HRP20000494B1 (en) Pharmaceutically active morpholinol
ATE87481T1 (de) Orale arzneimittelformen von pimobendan.
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
ITMI941262A0 (it) Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
UY27373A1 (es) Formulaciones de interferón beta-humano
RU2000104099A (ru) Средство для локальной противоревматической терапии
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
RU2001128736A (ru) Способ нормализации воспроизводительной функции коров
IT1309464B1 (it) Apparecchio per laserterapia.
ATE302582T1 (de) Haartonikum mit l-arginin als wirkstoff
DK1086695T3 (da) Antivirale præparater omfattende yohimbin som aktivt princip
IT1310896B1 (it) Articolatore per odontotecnica.
ES2052701T3 (es) Agente hipouricemico que contiene ponalrestat.
EP1210949A4 (en) MEDIUM WITH ANTIULCUS EFFECT
RU2000125446A (ru) Ветеринарный препарат для лечения гипотиреоза у крупного рогатого скота
ES1044804Y (es) Contenedor para pilas usadas.
ES1044269Y (es) Mesa camilla desmontable.
IT247359Y1 (it) Trave composta per solaio.
ITBO990038A0 (it) Pomata per la cura delle lesioni cutanee particolarmente delle ustioni .
IT1311630B1 (it) Perfezionamento ad una struttura di vassoio isotermico,particolarmente per la somministrazione delle vivande alle comunita'.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees